Regulatory Jobs

ICH Q9(R1) Pushes Quality Risk Management From Checkbox to Formal Discipline

ICH Q9(R1) tightens how pharma and biotech companies have to justify their quality risk decisions, and it's raising the bar for who gets hired to lead them.

Connor Griggs

Connor GriggsMSRACQA

Founder & Editor-in-Chief

6 min read

Introduction

Quality risk management has existed as a named discipline in pharmaceutical manufacturing since 2005, when the original ICH Q9 guideline gave the industry a shared vocabulary for identifying, assessing and controlling risks to product quality. For most of the time since, in a lot of organizations, that vocabulary showed up mainly in deviation investigations and CAPA justifications — a risk matrix filled in because the SOP required one, not because it was driving a decision. The revision, ICH Q9(R1), was written specifically to close that gap, and it's changing what quality teams are expected to produce and who they need on staff to produce it.

None of this is really about new science. It's about rigor, documentation and the uncomfortable fact that a lot of risk assessments across the industry were, by the revision's own framing, more subjective and less consistent than the people relying on them assumed.

What Q9(R1) Actually Changes

The revision adds two concepts that weren't spelled out clearly in the original guideline. The first is formality: an explicit expectation that organizations decide, and can justify, how rigorous and how documented a given risk assessment needs to be. A low-complexity, well-understood risk might reasonably get a brief, informal assessment. A novel manufacturing change with high uncertainty and high stakes needs a formal process, often using a named tool like failure mode and effects analysis, with documented assumptions and a traceable rationale. Q9(R1) asks companies to be deliberate about that choice rather than defaulting to whatever level of rigor is easiest to produce on a deadline.

The second is a direct acknowledgment of subjectivity and bias in risk assessments. Earlier guidance treated risk tools as if a team using them correctly would arrive at an objective answer. The revision is more honest about the fact that the people running the assessment, their assumptions, and the way a question gets framed all shape the outcome, and it expects organizations to build in practices that reduce that bias — diverse subject-matter input, challenge sessions, documented assumptions that someone outside the room could review and understand.

A third addition deals with product availability: the guidance explicitly recognizes that decisions aimed at eliminating quality risk can sometimes create or worsen supply risk, and it asks organizations to weigh both rather than treating supply continuity as someone else's problem. That's a meaningful shift given how much attention drug shortages have drawn from regulators and the public in recent years.

Why a Documentation Update Matters for Hiring

It's tempting to read a guideline revision like this as a paperwork change that quality teams absorb without much disruption. In practice, formality and bias-mitigation requirements don't implement themselves. Someone has to decide, function by function, what the organization's formality criteria actually are; someone has to train assessment teams on tools like FMEA, hazard analysis and fault tree analysis well enough that those tools get used correctly rather than performed badly to satisfy an auditor; and someone has to own the quality risk management program as its own discipline rather than a sidebar inside deviation management.

That's creating hiring demand for roles explicitly built around quality risk management — risk management leads, QRM program owners, and senior quality professionals whose job includes building out the formality framework and defending it when an inspector asks why a particular assessment was handled the way it was. It's also raising the floor for existing quality roles: a CAPA investigator or a quality engineer who could previously get by filling in a risk matrix from memory now needs real fluency in the tools and in the newer expectation that assumptions and potential bias get documented, not just the conclusion.

How This Shows Up in Day-to-Day Quality Work

The practical effects are visible across several parts of a quality system. Supplier qualification decisions increasingly need an explicit risk rationale for why a supplier was audited at a particular depth rather than another. Specification-setting and validation approaches for new products are expected to show how risk assessment informed the level of testing or validation chosen, rather than defaulting to the most conservative option by habit. Change control records for manufacturing changes need to show not just that a risk assessment happened, but why it was scoped the way it was and who was involved in challenging the initial assumptions.

Deviation and CAPA work, the area where risk matrices have always been most common, is also affected, just less dramatically. The tool itself often stays the same; what changes is the expectation that the assessment records who was in the room, what assumptions they started from, and why the resulting risk rating was judged high, medium or low rather than just stating the rating as a number pulled from a matrix. An investigator who can't reconstruct that reasoning six months later, when a similar deviation recurs and someone asks why the first one was closed as low risk, is exactly the gap Q9(R1) is aimed at closing.

None of this eliminates judgment from quality decision-making — if anything, it makes the judgment more visible, because the reasoning behind a formality decision now has to be written down in a way a reviewer, auditor or new team member could follow without the original author in the room to explain it.

The Supply Risk Tension Regulators Are Now Naming Directly

The product availability piece of the revision deserves its own attention, because it pushes against an instinct that's built into a lot of quality cultures: when in doubt, choose the more conservative option. Rejecting a borderline batch, tightening a specification, or requiring additional testing before release all look like the safer call from a pure quality-risk perspective. Q9(R1) asks organizations to also weigh what happens if that caution removes supply from the market, particularly for products with few alternative sources or where a shortage has direct patient consequences.

That doesn't mean the guidance tells companies to accept more quality risk to protect supply. It means the decision has to explicitly weigh both risks side by side, with the tradeoff documented, rather than letting the quality-risk side win by default because it's the more familiar kind of risk to reason about. For a quality team, that's a genuinely different kind of conversation than a standard risk assessment, and it often pulls supply chain and commercial stakeholders into a discussion that used to stay entirely inside quality.

What This Means If You're Building a Quality Career Around It

For people already working in quality, the practical takeaway is to get genuinely competent with the standard risk tools rather than treating them as a form to complete. Organizations that are serious about implementing Q9(R1) are looking for quality professionals who can run a defensible FMEA, facilitate a risk assessment without steering it toward a predetermined answer, and explain a formality decision in plain language to someone outside the room. That combination of technical tool fluency and facilitation skill is less common than baseline quality knowledge, which is part of why it's becoming a differentiator in hiring for quality roles above the entry level.

How Fast This Reaches Inspection Floors

Guideline revisions like this don't flip a switch across the industry on a single date. ICH guidelines get adopted into each region's own regulatory framework and inspection practice on its own timeline, and companies vary widely in how quickly they update internal SOPs to reflect a revision once it's finalized. The practical effect is a multi-year window where inspectors are increasingly likely to ask pointed questions about formality and documented rationale, while plenty of sites are still running risk management programs built to the older, less explicit expectations. That gap is exactly where the hiring pressure shows up first: companies that want to get ahead of it, rather than scramble to catch up after an inspection finding, are the ones building out dedicated quality risk management capability now rather than waiting for a citation to force the issue.

Conclusion

ICH Q9(R1) doesn't ask companies to manage new risks; it asks them to manage the risks they already had more honestly, with more documented rigor and less unexamined subjectivity. That's a modest-sounding change that turns out to touch supplier management, change control, validation strategy and deviation handling all at once, and it's pulling quality risk management out of the deviation-report sidebar and into something closer to its own specialty. For quality professionals, fluency in that specialty is quickly becoming less of a nice-to-have and more of a baseline expectation, and for anyone deciding where to focus their next round of professional development inside a quality career, formal risk assessment facilitation is a reasonably safe bet on where the bar is heading.

Regulatory & Quality. REWIRED.

New roles. Real pay. Your next move.

  • Hand-picked roles, every week.
  • The newest company pages.
  • One article worth your time.
Get the Weekly

Free. Thursday mornings. One-click unsubscribe.

Connor GriggsConnor Griggs

About the author

Connor GriggsMSRA, CQA

Founder & Editor-in-Chief

Connor began his career as a regulatory analyst at the FDA and has spent 13 years in medical device regulatory affairs and quality.

Find your next regulatory or quality role

Every role on Regulatory Jobs is in regulatory, quality or clinical, in pharma, biotech or medical devices. Set an alert and the next one reaches you the day it posts.

Next in News & UpdatesWhat FDA's QMSR Means for Regulatory and Quality Careers in Medical Devices